# Safety and Efficacy of Baricitinib After Endovascular Treatment in Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized Controlled Clinical Trial

Study · id `cardio:ct-nct07449910` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07449910](<https://clinicaltrials.gov/study/NCT07449910>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07449910

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 750 participants.

## Technical summary

Registry record NCT07449910. Randomized; quadruple masking; primary purpose treatment. Start 2026-03-17 (anticipated); primary completion 2027-08-17 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 750 participants (planned count; ClinicalTrials.gov record NCT07449910, source copy `cardio:ctgov-nct07449910-2026-03-04`, retrieved 2026-10-26)
- Planned start: 2026-03-17 (anticipated) (ClinicalTrials.gov record NCT07449910, source copy `cardio:ctgov-nct07449910-2026-03-04`, retrieved 2026-10-26)
- Primary completion: 2027-08-17 (anticipated) (ClinicalTrials.gov record NCT07449910, source copy `cardio:ctgov-nct07449910-2026-03-04`, retrieved 2026-10-26)
- Completion: 2028-01-31 (anticipated) (ClinicalTrials.gov record NCT07449910, source copy `cardio:ctgov-nct07449910-2026-03-04`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07449910, source copy `cardio:ctgov-nct07449910-2026-03-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07449910-2026-03-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of Baricitinib After Endovascular Treatment in Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized Controlled Clinical Trial
- Condition: Acute Ichemic Stroke
- Condition: Anterior Cerebral Artery Stroke
- Condition: Baricitinib
- Intervention (Drug): 2mg Baricitinib
- Intervention (Drug): 4mg Baricitinib
- Intervention (Drug): Placebo
- Intervention (Other): Guideline-based therapy
- Lead sponsor: The First Affiliated Hospital of University of Science and Technology of China
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: The First Affiliated Hospital of University of Science and Technology of China (`cardio:org-the-first-affiliated-hospital-of-university-of-science-and-03d159`)

## Provenance

Content hash: 60b0bcb518203649cbc8d7498a63deffbb7e47fc2788aff1186718f3b65b1034
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
